

CUMULATIVE INDEX 1996

Volume 16

March	DNA TECHNOLOGY, pages 1-249
June	HEPATITIS AND CHRONIC LIVER DISEASE, pages 251-512
September	CLINICAL MYCOBACTERIOLOGY, pages 513-779
December	BLOOD BANKING, pages 781-1011

Note: Page numbers of article titles are in **boldface** type

- ABH antigens, platelet, 818
- ABO antigens, matching of, computers in, 956-957
 - in platelet transfusions, 806-807
- platelet, 806-807, 817-818
- N-Acetylcysteine, in hepatitis C, 484
- in mycobacterial specimen decontamination, 558-559
- Acid-base imbalance, in massive transfusions, 876
- Acid-fast bacteria, smears of, interpretation of, 554-557
 - microscopic examination of, 553-554
 - in developing countries, 705-707
 - predictive value of, 556-557
 - preparation of, 556, 681
 - quality control of, 658-659
 - safety with, 530
 - test sensitivity of, 667-668
- Acidosis, metabolic, in massive transfusions, 876
- Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.
- Activated partial thromboplastin time, 849-850
 - abnormal, differential diagnosis of, 850-852
- Activated protein C and/or A, resistance to, 169-186
 - etiology of, 171-173
 - evaluation of, 861-862
 - factor V gene mutation in, 173-183
 - biochemistry of, 173-175
 - laboratory evaluation of, 176-183
 - multifactorial, 176
 - thrombosis risk in, 175-176
 - pathogenesis of, 170-171
- Adenosine deaminase deficiency, gene therapy for, 200-201
- Adhesion molecules, in liver, 364
- Adrenal hyperplasia, congenital. See *Congenital adrenal hyperplasia*.
- Adsorption columns, in apheresis, 919-921
- Aerosols, of mycobacteria, sources of, 529
- Affinity adsorption apheresis, 919-921
- Aflatoxin, hepatitis B and, 255-256
- Agar disk diffusion method, in drug susceptibility testing, of atypical mycobacteria, 653
- Agar disk elution method, in drug susceptibility testing, of atypical mycobacteria, 653
- Agar 7H11 plates, in drug susceptibility testing, of mycobacteria, 644-645
- AIDS. See *Human immunodeficiency virus infection*.
- Air filters, for biological safety cabinets, in mycobacteriology, 530-535
- Alanine aminotransferase, in hepatitis B, in interferon therapy, 467-473
 - in hepatitis C, in interferon therapy, 476-481
- Albumin, as replacement fluid, in apheresis, 916
- Alcohol, blood, testing for, consent for, 942
- hepatitis B virus interactions with, 255, 273-287, 289-306
 - animal studies of, 293-295
 - apoptosis and, 299-301
 - carcinogenic effects of, 278-280, 402
 - cytokines and, 295-297
 - dietary influences on, 292
 - mechanisms of, 275-276

Alcohol (*Continued*)

- prevalence of, 274
- regeneration inhibition in, 293-299
- serologic patterns in, 276-278
- signal transduction alterations in, 293
- hepatitis C virus interactions with, 264-265, 273-287, 289-306
- animal studies of, 293-295
- apoptosis and, 299-301
- carcinogenic effects of, 280-281, 402-403
- cytokines and, 295-297
- dietary influences on, 292
- mechanisms of, 275-276
- prevalence of, 274
- regeneration inhibition in, 293-299
- serologic patterns in, 278
- signal transduction alterations in, 293
- hepatitis D and, 258, 460
- in hepatocellular carcinoma, 378, 386-390
- chemical carcinogen interactions in, 386-388
- hepatitis virus interactions in, 388-390
- metabolism of, in liver, 275, 292
- Alcoholic liver disease, fibrogenesis in, 371
- Alkalosis, metabolic, in massive transfusions, 876
- Alloimmunization, in platelet transfusions, 828-829
 - prevention of, 785-786
 - reduction of, 800-803, 810
- Alzheimer's disease, apolipoprotein E polymorphism in, 111-112
- Aminosalicylic acid, pharmacokinetics of, 720-721
- Amplicor systems, for Chlamydia testing, evaluation of, 52-59
- Amplification techniques, in mycobacteriology, 682-685. See also *Polymerase chain reaction*.
- Gen-Probe MTD system (transcription-mediated), 632-634, 682-683
- principles of, 617-619
- Amplified fragment length polymorphism, in forensic testing, 190
- Anaphylactic reactions, in plasmapheresis, angiotensin-converting enzyme inhibitors and, 917-918
- Ancrod time test, in coagulation disorders, 854
- Androgens, excessive production of, in congenital adrenal hyperplasia, 125-126
- Angiocentric immunoproliferative lesion, DNA analysis in, 2
- Angiotensin-converting enzyme inhibitors, impact of, in apheresis, 917-918

- Animal models, for hepatocellular injury, in hepatitis, 309-310
- Antibodies, intracellular, in gene therapy, 204
- platelet. See *Platelet(s)*, antibodies to.
- removal of, apheresis in, 919-921
- to hepatitis viral antigens. See specific viruses.
- Anticholesterol agents, blood lipid levels and, in apolipoprotein E polymorphism, 113
- Anticoagulants, lupus, measurement of, 858-859
- Antigens, of hepatitis viruses. See specific viruses.
- platelet. See *Platelet(s)*, antigens of.
- Antimycobacterial drugs, in mycobacterial infections, susceptibility testing of. See *Drug susceptibility testing*, of *mycobacteria*.
- therapeutic monitoring of, 717-729
 - assay methods and technology for, 723-725
 - mechanisms of action and, 719
 - pharmacodynamic parameters of, 719
 - pharmacokinetic parameters of, 718-721
 - practical issues in, 722-723
 - results interpretation in, 725-727
- Antiphospholipid antibodies, measurement of, 858-859
- Antisense oligonucleotides, in gene therapy, 203
- Antisense therapy, for neoplasia, 207-208
- Antithrombin III, deficiency of, evaluation of, 859
 - in coagulation regulation, 846
- Apheresis, 907-929
 - affinity adsorption, 919-921
 - for granulocyte harvesting, 914-916
 - for stem cell harvesting, 907-914
 - of platelets, 800-801
 - phototherapy with, 921-922
 - reactions during, 917-918
 - replacement fluids for, 916
 - versus intravenous immunoglobulin treatment, 919
- Apolipoprotein E, polymorphism of, 105-123
 - cholesterol reduction therapy and, 112-113
 - genotype analysis in, 114, 116
 - genotype frequencies in, 116-117
 - in Alzheimer's disease, 111-112
 - in atherosclerosis, 110-111
 - in cerebrovascular disease, 112
 - in coronary artery disease, 110-111
 - in hyperlipoproteinemia, 106, 108-110
 - in peripheral vascular disease, 112
 - lipoprotein receptor binding and, 106-107

- phenotype analysis in, 113-114
 posttranslational modification in, 106
- Apoptosis, bcl-2 gene rearrangements and, 30
 of liver cells, alcohol effects on, 299-301
- Arylsulfatase, in mycobacterial
 identification, 572, 578, 581, 583, 587
- Asians, hepatitis B in, interferon in, 471-472
- Aspergillosis, in immunodeficiency, 78
- Association of State and Territorial Public Health Laboratory Directors, 731-743
 assessment activities of, 732-735
 conferences of, on mycobacteriology, 737-738
 fellowship program of, 740-741
 information transfer by, 740
 mission of, 731
 Pacific Islands laboratory case study of, 736-737
 policy development by, 735-738
 quality assurance activities of, 739-742
 self-assessment tools of, 741-742
 training programs of, 739-741
- Ataxia-telangiectasia, breast cancer in, 148
- Atherosclerosis, apolipoprotein E polymorphism in, 110-111
 gene therapy for, 201-202
- ATM gene, DNA analysis of, direct, 154
 mutations of, in ataxia-telangiectasia, 148
- Auramine rhodamine stain, for acid-fast bacteria, 554-555
- Autoimmune disorders, photopheresis in, 922
- Autoimmune thrombocytopenic purpura, platelet antibodies in, 829-831
- Autolymphocyte therapy, in gene therapy, for neoplasia, 206
- Automation, in mycobacteriology, culture equipment, 560, 562-563
 of polymerase chain reaction, 217-219
- Autopsy, consent for, 938-939
- Azithromycin, in mycobacterial infections, 641
- B lymphocytes, gene rearrangement in, hematopoietic disorders, 1-21
- BACTEC 12B system, in mycobacteriology, nucleic acid probes in, 608
- BACTEC NAP system, in mycobacteriology, quality control of, 661
- BACTEC systems, in mycobacteriology, in drug susceptibility testing, 645-646
 of *Mycobacterium avium* complex, 648-650
 p-nitro- α -acetylaminobenzylhydroxypropylphenone in, 604-605
- procedure for, 560-564
 safety in, 530-531
- BACTEC TB system, cross-contamination in, prevention of, 666-667
- Bak antigens, platelet, 819
- Balloon cell degeneration, in liver disease, 290
- Battery, unauthorized treatment as, 932-933
- B-cell lymphoproliferative disorders, in transplantation, 13-16
- bcl-2 gene, 23-47
 IgH locus of, 27-28
 normal, 26
 protein of, function of, 29-31
 rearrangements of, in lymphoid malignancies, 23-24
 detection of, 31-39
 diffuse lymphoma, 40
 follicular lymphoma, 39-40
 fusion with 2JH, 28-29
 Hodgkin's disease, 41
 molecular events in, 25-26
 prognostic value of, 42-43
 protein function in, 29-31
 small noncleaved cell lymphoma, 40-41
 tissue localization of, 42
- Benches, horizontal laminar flow, in mycobacteriology, 535-536
- Bethesda assay, for coagulation factor inhibitors, 856-857
- Biocontainment, in mycobacteriology, primary, 531-538
 secondary, 538
- Biohazard bags, in mycobacteriology, 541
- Biological safety cabinets, in mycobacteriology, certification of, 536
 class I, 531-532
 class II, 532-535
 location of, 538
 operational suggestions for, 536-537
- Biosafety. See *Safety*.
- BITS computer program, in blood typing training, 957-958
- Blood, typing of, computers in, 957-958
- Blood banking, apheresis, 907-929
 coagulation and, 837-871
 error detection and reduction in, 961-973
- informatics in, 947-960
 legal issues in, 931-946
 massive transfusion and, 873-882
 mathematical calculations in, 895-906
 platelets, 797-816
 antibody detection, 817-835
 modified, 781-795
 red cells, modified, 781-795
 safety in, 975-988

- Blood banking (*Continued*)
 testing in, decision making for, model for, 883-893
- Blood culture, of mycobacteria, 561-562
- Blood products, hepatitis C in, 260-261
- Blood volume, estimation of, 896
- Bone marrow transplantation, recurrent leukemia in, stem cell transplantation in, 913
- Boosters, for hepatitis B vaccine, 496
- Br antigens, platelet, 819
- BRCA1 gene, 139-141
 DNA analysis of, direct, 153-156, 159-160
 functional detection of mutations of, 158-159
 informed consent for, 162-163
 linkage analysis in, 152-153
 mutation screening methods for, 155-158
 tests for, 149, 151-152
 identification of, 142-143, 145-146
 in ataxia-telangiectasia, 148
 in Muir-Torre syndrome, 147
 penetrance of, 145
 protein of, characteristics of, 146
- BRCA2 gene, 146-147
 DNA analysis of, informed consent for, 162-163
- Breast cancer, hereditary, 139-167
 BRCA1 gene in. See BRCA1 gene.
 BRCA2 gene in, 146-147, 162-163
 clinical features of, 143-144
 epidemiology of, 144-145
 genotyping of, 140-141
 in males, 146-147
 molecular diagnosis of, direct DNA detection in, 153-155, 159-160
 functional detection of mutations in, 158-159
 future directions in, 161
 historical perspective of, 148-151
 informed consent in, 162-163
 linkage analysis in, 152-153
 mutation screening methods in, 155-158
 practical considerations in, 161-162
 tests for, 148-151
 phenotyping of, 140-141
 risk assessment in, 144-145
 syndromes associated with, 143-144, 147-148
 TP53 gene in. See TP53 gene.
 tumor suppressor gene inactivation in, 139
 tumors associated with, 143-144
- Bronchial alveolar lavage, in specimen collection, for mycobacteriology, 552
- Broth microdilution method, for drug susceptibility testing, of atypical mycobacteria, 652-653
- Burns, fungal infections in, 79
- Caat enhancer binding protein, in liver regeneration, 345-347
- Cancer, gene therapy for, 205-208
 liver. See Hepatocellular carcinoma.
 transfusions in, immunosuppressive effects of, 789-790
- Candidemia, clinical features of, 74-75
- Candidiasis, in immunodeficiency, clinical features of, 74-77
 DNA analysis of, 77-78, 80-82, 85
 nosocomial, epidemiology of, 82-85
 typing of, 80-85
- Candiduria, in immunodeficiency, 76-77
- Capreomycin, pharmacokinetics of, 720-721
- Carbon usage test, in mycobacterial identification, 583, 587-588
- Carbonic anhydrase II deficiency, genetic studies of, 213-214
- Carcinogens, chemical, in hepatocellular carcinoma. See Hepatocellular carcinoma.
 hepatitis B virus as, 395-400, 494-495
 hepatitis C virus as, 400-401, 494-495
- Carcinoma, hepatocellular. See Hepatocellular carcinoma.
- Carriers, of hepatitis B, therapeutic vaccines for, 501
 of hepatitis C, therapeutic vaccines for, 501
- Catalase, in mycobacterial identification, 572, 578, 581, 583, 588-589
- Cell lysis, in polymerase chain reaction, 619
- Centrifugation, of mycobacterial samples, safety with, 529-530
- Cerebrovascular disease, apolipoprotein E polymorphism in, 112
- Cetyl pyridium chloride, in mycobacterial specimen decontamination, 558
- Chemical carcinogens, in hepatocellular carcinoma. See Hepatocellular carcinoma.
- Chemical mismatch cleavage analysis, in breast cancer, 157-158
- Chemiluminescence, for polymerase chain reaction, in mycobacteriology, 632-634
- Chemoprotection, in chemotherapy, multidrug-resistant gene modification in, 207
- Chemotherapy, myelosuppressive, in stem cell mobilization, for apheresis, 909-910

- thrombocytopenia in, affinity adsorption apheresis in, 921
- Chlamydia trachomatis*, detection of, Amplicor product in, evaluation of, 52-59
- multiplex polymerase chain reaction in, 64-68
- Cholesterol, blood profiles of, in apolipoprotein E polymorphism, 107-110
- atherosclerosis and, 110-111
- therapy effects on, 112-113
- drugs lowering, apolipoprotein E polymorphism and, 113
- Choline deficiency, in alcohol abuse, hepatocellular sensitivity to, 292
- Chromatography, in mycobacterial identification, gas-liquid, 605-606
- high-pressure liquid, 606-607
- liquid, quality control of, 661-662
- Chromogenix Coatest, in activated protein C resistance detection, 183
- Cirrhosis, as fibrogenesis sequelae, 371
- hepatocellular carcinoma in, 378
- in hepatitis B, 255, 273-274
- interferon in, 471
- malignant transformation of, 399, 402
- in hepatitis C, 273-274
- malignant transformation of, 401-403
- in hepatitis D, 258, 456-457
- liver regeneration in, 355
- prevention of, hepatitis vaccines for, 493-505
- Citrate effect, in massive transfusions, 878
- Clarithromycin, in mycobacterial infections, 641
- Clinical Laboratory Improvement Amendments, proficiency testing regulations of, 670-671
- Clofazimine, pharmacokinetics of, 720-721
- Clofibrate, in hepatocellular carcinoma, 383
- Clot formation, 843-844
- Clothing, protective, for mycobacteriology, 540-541
- Coagulation, 837-871
- contact system in, 844-845
- disorders of, activated protein C and A resistance. *See Activated protein C and/or A, resistance to.*
- evaluation of, 852-862
- factor activity assays in, 854-856
- factor inhibitor assays in, 856-858
- in activated protein C resistance, 861-862
- in antithrombin III resistance, 859
- in lupus anticoagulants, 858-859
- in protein C deficiency, 860
- in protein S deficiency, 860-861
- thrombin time in, 853-854
- in massive transfusions, 876-878
- evaluation of, 848-852
- factor V in, 838-839
- factor VIII in, 838-839
- factor X activation in, 842-843
- fibrin clot formation in, 843-844
- initiation of, 840-842
- overview of, 837-838
- pathways for, 840-842
- platelets in, 839-840
- regulation of, 845-847
- thrombin in, 839, 843
- vitamin K-dependent factors in, 838-839
- Coagulation factors, activity levels of, assays for, 854-856
- calculation of, 903-905
- deficiencies of, in massive transfusions, 877
- inhibitors of, assays for, 856-858
- Collagens, in liver, 361-362
- gene expression regulation in, 370-371
- College of American Pathologists, proficiency testing regulations of, 670-672
- Colonial morphology, in mycobacterial identification, 572, 578, 581, 583, 589-590
- Colony-stimulating factors, in granulocyte mobilization, for apheresis, 915
- in hepatic fibrogenesis, 367-368
- in stem cell mobilization, for apheresis, 909-910
- Commercial systems, for polymerase chain reaction, in mycobacteriology, 630-631
- Compatibility testing, for transfusions, computers in, 956-958
- mathematical calculations in, 901
- platelet, 809-810
- ABO matching for, 806-807
- Rh type matching for, 807
- Competency, for informed consent, 936-937
- Computers, in information processing. *See Informatics.*
- Confidential unit exclusion, in blood donation, 978
- Congenital adrenal hyperplasia, 125-137
- clinical features of, 125-126
- diagnosis of, 126, 131-132
- gene involved in, 126-128
- genotype-phenotype relationships in, 132-135
- molecular genetics of, 128-131
- Conjunctiva, lymphoma of, 7-11
- Consent. *See Informed consent.*
- Contact system, in coagulation, 844-845
- Contraceptives, oral, thrombosis risk in, factor V gene mutation and, 176
- Contract negotiation, for pathology practice networking, 238-239

- Coronary artery disease, apolipoprotein E polymorphism in, 110-111
gene therapy for, 201-202
- Corticosteroids, in granulocyte mobilization, for apheresis, 915
in hepatic fibrogenesis inhibition, 368
- Cortisol, replacement of, in congenital adrenal hyperplasia, 126
- Cost-effectiveness, in mycobacteriology, in test utilization reduction, 754-755
strategies for, 686-689
of pathology practice networking, 237
- Cowden's disease, breast cancer in, 147-148
- Credentialing, standard, for pathology practice networking, 236
- Crossmatching, for transfusion, mathematical probability of, 901
- Cryoglobulinemia, mixed, in hepatitis C, treatment of, 481-482
- Cryptantigens, on platelets, 820
- Cultures, mycobacterial, blood, 561-562
preparation of, 559-565, 681-682
in developing countries, 706
quality control of, 660-661
safe handling of, 543-548
slide, in drug susceptibility testing, 648
specimen decontamination for, 558-559, 660
- Cycloserine, pharmacokinetics of, 720-721
- CYP21 genes, in 21-hydroxylase deficiency, 127-131
- Cystic fibrosis, gene therapy for, laboratory implications of, 209
- Cytokines, in alcohol consumption, 275-276
liver regeneration and, 295-297
in granulocyte mobilization, for apheresis, 915
in liver regeneration, 328-333, 350-354
in stem cell mobilization, for apheresis, 912-913
- Cytomegalovirus, removal of, from blood components, 787-788, 803
- Cytopathic effect, in hepatocellular injury, in hepatitis, 308, 317
- Cytotoxic gene therapy, for neoplasia, 206-207
- Decision making, in blood banking, model for, 883-893
- Decontamination, of specimens, for mycobacterial culture, 558-559
quality control of, 660
- Deferral registry, in blood donation, 941, 950
- Delta hepatitis. See *Hepatitis D*.
- Denaturing gradient gel electrophoresis, in breast cancer, 155, 157
- Developing countries, mycobacteriology in. See *Mycobacteriology, in developing countries*.
- Dexamethasone, in congenital adrenal hyperplasia, 126
- Diabetes mellitus, gene therapy for, 201
- Diet, blood lipid levels and, in apolipoprotein E polymorphism, 113
in alcohol abuse, hepatocellular sensitivity to, 292
- Digoxigenin, in polymerase chain reaction detection step, 625-626
- Direct automatic sequencing, in breast cancer gene analysis, 154-155
- Direct tests, of drug susceptibility, of mycobacteria, 643-645, 647-648
- Dithiothreitol, in mycobacterial specimen decontamination, 558
- DNA, amplification of, polymerase chain reaction in. See *Polymerase chain reaction*.
storage of, on Guthrie cards, 216
- DNA probes, in mycobacteriology, 573, 578, 581
quality control of, 661
- DNA technology, apolipoprotein E polymorphism, 105-123
detection methods in, 218
future developments in, 213-222
guidelines for, 215-217
in activated protein C and A resistance, 169-186
in congenital adrenal hyperplasia, 125-137
in forensic testing, 187-196
in fungal infections, in immunodeficiency, 73-88
in gene therapy, 197-211
in hematopoietic disorders, B and T cell gene rearrangement, 1-21
in hereditary breast cancer, 139-167
in HIV infection, nucleic acid sequence-based amplification, 89-103
in 21-hydroxylase deficiency, 125-137
in lymphoid malignancies, bcl-2 gene rearrangements, 23-47
in sexually transmitted diseases, multiplex polymerase chain reaction, 61-71
proportion of total test volume, 214-215
role of, 49-60
enthusiasm for, 50-51
example of, Chlamydia Amplicor evaluation as, 52-59
skepticism about, 51-52
- Donors, blood, computerized interview of, 949-950
follow-up of, 982-983

- for platelet transfusions, 800-801
- informed consent for, 940-941
- laboratory testing of, 978-982
 - decision making model for, 883-893
 - screening of, 948-951
 - selection of, 975-978
- Dot blot test, in breast cancer gene mutation detection, 160
 - in forensic testing, 189-190
- Drug(s), thrombocytopenia from, 831-832
 - autoimmune, 830-831
- Drug resistance, in tuberculosis, 515
 - in developing countries, 699-701
 - testing of. *See Drug susceptibility testing.*
- Drug susceptibility testing, of
 - mycobacteria, 641-656, 685-686, 690
 - BACTEC indirect qualitative test in, 645
 - BACTEC indirect quantitative test in, 645-646
 - in developing countries, 707
 - luciferase indirect qualitative test in, 646-647
 - methods for, 642-643
 - principles of, 641-644
 - proportion method in, 644-645
 - quality control of, 662-663
 - slide culture direct test in, 647-648
 - of *Mycobacterium avium* complex, 648-652
 - of *Mycobacterium fortuitum-chelonae*, 652-653
 - of *Mycobacterium marinum*, 652-653
 - of *Mycobacterium tuberculosis*, 643-648
- Educational intervention, for test utilization control, 759-760
- Elastin, in liver, 362
- Electrochemiluminescence method, in nucleic acid sequence-based amplification, 94, 96-97
- Electroimmunoassay, for platelet antibodies, 824
- Electronic teleconferencing, for pathology practice networking, 235-236
- Electrophoresis, contour-clamped homogenous gel, in fungal typing, 81-82
 - denaturing gradient gel, in breast cancer, 155, 157
 - rocket, for platelet antibodies, 824
- Endotoxin, in alcohol consumption, liver regeneration and, 297
- Entactin, in liver, 362-363
- Enzyme immunoassay, for hepatitis C virus, 259
- Enzyme-linked gel assay, in nucleic acid sequence-based amplification system, 94-95
- Epidemiology, of viral hepatitis, 251-271
 - hepatitis B, 251-256
 - hepatitis C, 258-265
 - hepatitis D, 256-258
- Epithelial cells, hepatic, in liver regeneration, 326-328
- Errors, in blood banking. *See Transfusion therapy, error detection and reduction in.*
- Erythrocytes. *See Red blood cells.*
- Esophagus, candidiasis of, in immunodeficiency, 75
- ESP System, for mycobacterial culture, 562-563
- ESPRE expert system, for platelet transfusion ordering, 955-956
- Ethambutol, pharmacokinetics of, 720-721
- Ethanol. *See Alcohol.*
- Ethidium bromide, in polymerase chain reaction detection step, 625
- Ethionamide, pharmacokinetics of, 720-721
- Exchange transfusion, whole blood reconstitution for, 898-899
- Expert systems, for blood donor suitability, 951
- Extracellular matrix, hepatic, components of, 361-364
 - degradation of, 365
 - enhanced production of, 364-365
 - homeostasis of, 364-365
 - in liver regeneration, 333-334
 - regulatory signals in, 367-368
- Extracellular transplantation, gene therapy in, 208
- Extraction, in polymerase chain reaction, 619-620
- Eye protection, for mycobacteriology, 540
- Factor V, gene mutations in, in activated protein C and/or A resistance, 173-183
 - biochemistry of, 173-175
 - laboratory evaluation of, 176-183
 - multifactorial, 176
 - thrombosis risk in, 175-176
- in coagulation, 838-839
- Factor VIII, in coagulation, 838-839
 - transfusion of, calculations for, 904-905
- Factor X activation, 842-843
- Factor XI, in coagulation, 844-845
- Factor XII, in coagulation, 844-845
- Factor XIII, activity of, measurement of, 856
- Famcyclovir, in hepatitis B, 474
- Familial combined hyperlipidemia, apolipoprotein E polymorphism in, 110
- Fetal-maternal hemorrhage, volume of, estimation of, 905

- Fialuridine, in hepatitis B, 475
- Fibrillin, in liver, 362
- Fibrin clot formation, 843-844
- Fibrinogen, activity levels of, assays for, 855-856
in coagulation, 843
- Fibroblasts, autologous, in gene therapy, for neoplasia, 206
- Fibrogenesis, hepatic, 361-375
augmenters of, 367-368
cell types involved in, 366-367
collagen gene expression and, 370-371
extracellular matrix enhanced production in, 364-365
in alcoholic liver disease, 371
in viral hepatitis, 371-372
inhibitors of, 368
sequelae of, 371
stellate cell proliferation in, 368-370
versus extracellular matrix degeneration, 365-366
versus normal extracellular matrix, 361-364
- Fibronectin, in liver, 362
- Fibrosing cholestatic hepatitis, hepatitis B virus variants in, 420
- Filtration, of blood component cells, for transfusion, 783-784
- Financial system, standardized, for pathology practice networking, 237-238
- Flaviviruses, hepatitis C virus as, 258
- Fluid therapy, replacement, in apheresis, 916
with massive transfusions, 874
- Fluorescent stains, for acid-fast bacteria, 554-555
- Forensic testing, DNA technology in, 187-196
history of, 187-188
legal aspects of, 192-193
methods for, 188-191
quality control in, 191-192
regulatory aspects of, 191-192
- Freezing and thawing, of blood component cells, for transfusion, 782-783
- Fulminant hepatitis, hepatitis B virus variants in, 419-420
- Fungal infections, in immunodeficiency, DNA analysis of, 73-88
aspergillosis, 78
candidiasis, 74-78, 80-85
in burns, 79
in transplantation, 79
laboratory aspects of, 80-82
zygomycosis, 78-79
- FV R506Q gene. See *Factor V, gene mutations in.*
- Gamma irradiation, of blood components, 791
- Gancyclovir, in hepatitis B, 473-474
- Gas-liquid chromatography, in mycobacterial identification, 605-606
- Gastric lavage, in specimen collection, for mycobacteriology, 552-553
- Gene(s), of hepatitis viruses. See under specific virus.
rearrangement of, bcl-2, in lymphoid malignancies, 23-47
in hematopoietic disorders. See *Hematopoietic disorders.*
- Gene therapy, 197-211
antisense, 207-208
clinical applications of, 198-199
cytotoxic, 206-207
extracellular transplantation and, 208
in infectious disease, 202-205
in monogenic disorders, 199-201
in multigenic disorders, 201-202
in neoplastic disease, 205-208
laboratory impact of, 209-210
metabolic suicide, 216
monitoring of, 209
tissue engineering and, 208
tumor suppressor, 207
- Genetic suppressor elements, in gene therapy, 204
- Genotoxic carcinogens, in hepatocellular carcinoma, 378-382
- Genotypes, of apolipoprotein E, analysis of, 114, 116
frequencies of, 116-117
of 21-hydroxylase deficiency gene, analysis of, 132-135
- Genotyping, of hepatitis C virus. See *Hepatitis C virus, variants of.*
- Gen-Probe MTD system, for polymerase chain reaction, in mycobacteriology, 632-634, 682-683
- Glomerulonephritis, in hepatitis C, treatment of, 482
- Gloves, for mycobacteriology, 540-541
- Glycerol, in freezing and thawing, of blood component cells, for transfusion, 782-783
- Graft-versus-host disease, in stem cell transplantation, 914
transfusion-associated, prevention of, blood component irradiation in, 791
- Granulocyte(s), transfusion of, 914-916
- Granulocyte colony-stimulating factor, in granulocyte mobilization, for apheresis, 915
in stem cell mobilization, for apheresis, 909-910
- Granulocyte-macrophage colony-stimulating factor, in stem cell mobilization, for apheresis, 909-910

- Growth factors, in stem cell mobilization, for apheresis, 909-910
- Growth-response genes, induction of, in liver regeneration, 342-344
- Guillain-Barré syndrome, treatment of, intravenous immunoglobulin in, 919
- Guthrie cards, in DNA storage, 216
- Hawthorne effect, in performance, 758
- Health care workers, hepatitis B in, 253
hepatitis C in, 260
- HELP blood ordering system, 954-956
- Hemagglutination assay, mixed passive, for platelet antibodies, 821
- Hematocrit, calculation of, 896
- Hematopoietic disorders, B and T cell gene rearrangement in, 1-21
angiocentric immunoproliferative lesion, 2-4
large granular lymphocytosis, 16-19
lymphoma, of mucosa-associated lymphoid tissue, 5-7
of skin, 11-13
small cell cleaved, 7-11
post-transplant B-cell lymphoproliferative disorder, 13-16
- Hematopoietic growth factors, in stem cell mobilization, for apheresis, 909-910
- Hemoglobin, incremental increase of, after transfusion, calculation of, 898
- Hemoglobin dissociation curve, shifting of, in massive transfusions, 875-876
- Hemorrhage, fetal-maternal, volume of, estimation of, 905
massive transfusions in. See *Transfusion therapy, massive transfusions in.*
- Hemostasis, primary, 840
protein C in, 170-171
secondary, 840
- Hepadnaviruses, 251-252. See also *Hepatitis B virus.*
- Hepatic fibrogenesis. See *Fibrogenesis, hepatic.*
- Hepatitis, fibrosing cholestatic, hepatitis B virus variants in, 420
fulminant, hepatitis B virus variants in, 419-420
- Hepatitis B, aflatoxin and, 255-256
alcohol and. See *Alcohol, hepatitis B virus interactions with.*
antigen-negative, 254
carriers of, 252-253
therapeutic vaccines for, 501
chronic, definition of, 253-254
cirrhosis in, 273-274
interferons in, 471
diseases associated with, 254-255
epidemiology of, 252-253
fibrogenesis in, 371-372
geographic distribution of, 396
hepatitis C coinfection with, hepatocellular injury in, 318-319
hepatitis D coinfection with, 258, 455-456, 459-460
interferons in, 472
hepatocellular carcinoma in, 255, 395-406
alcohol interaction in, 278-280, 292, 377, 388-390, 402
carcinogenic mechanisms in, 494-495
hepatitis C coinfection with, 401-402
liver regeneration and, 327-328
pathogenesis of, 493-494
prevention of, 495-500
hepatocellular injury in, 307-324
animal models for, 309-310
hepatitis C coinfection with, 318-319
human leukocyte antigen expression and, 310-314
interferon in, 311-314
patterns of, 307-308
viral antigens and, 314-317
in liver transplantation, interferons in, 473
incidence of, 252-253
interferons in, 467-473
clinical studies of, 468-471
in Asians, 471-472
in liver transplantation, 473
nonresponders to, 472
with cirrhosis, 471
with hepatitis D, 472
liver regeneration in. See *Liver, regeneration of.*
persistence of, 253-254
prevalence of, 252-253
prevention of, 495-500
serologic response in, 252
transmission of, 253
in blood transfusion, decision making model for, 883-893
prevention of, 976, 977-982
treatment of, 465-475
drugs for, 473-475
vaccines for, 495-500
virus of. See *Hepatitis B virus.*
- Hepatitis B virus, alcohol interactions with. See *Alcohol, hepatitis B virus interactions with.*
antibodies to, 252
antigens of, in alcohol consumption, 276-278
in chronic disease, 254
in hepatocellular injury, 314-317
in interferon therapy, 467-473
variants of. See *Hepatitis B virus, variants of.*

Hepatitis B virus (*Continued*)

- genes of, 252
 - core, 407-409, 415-420
 - envelope, 409, 415, 417-419
 - hepatocellular carcinoma and, 397-400
 - pre-core, 407-408, 415-420
 - surface, 411, 413, 421-423
 - X, 409, 411, 421
- in hepatitis D virus propagation, 451-452
- nomenclature of, 251-252
- structure of, 251-252
- variants of, 407-428
 - clinical significance of, 415
 - core genes, 407-409, 415-420
 - enhancers and, 421
 - hepatocellular injury and, 308
 - in fibrosing cholestatic hepatitis, 420
 - in fulminant hepatitis, 419-420
 - interferon and, 419
 - pre-core genes, 407-408, 415-420
 - promoters and, 421
 - small envelope proteins, 422-423
 - surface genes, 411, 413, 421-423
 - vaccines for, 500
 - X gene, 409, 411, 421
- X antigen of, alcohol and, 275, 277, 279-280
 - genes of, 409, 411, 421
- Hepatitis C, alcohol and. *See Alcohol, hepatitis C virus interactions with.*
- carriers of, therapeutic vaccines for, 501
- cirrhosis in, 273-274
- diseases associated with, 263-264
- fibrogenesis in, 371-372
- hepatitis D coinfection with, 460
- hepatocellular carcinoma in, 400-403
 - alcohol interaction in, 280-281, 292, 377, 388-390, 402-403
 - carcinogenic mechanisms in, 494-495
 - hepatitis B coinfection with, 401-402
 - liver regeneration and, 327-328
 - pathogenesis of, 493-494
 - prevention of, 495, 500-501
- hepatocellular injury in, 307-324
 - hepatitis B coinfection with, 318-319
 - mediators in, 317-318
 - patterns of, 307-308
- interferons in, clinical studies of, 476-481
 - in liver transplantation, 483
 - with extrahepatic manifestations, 481-482
- liver generation in. *See Liver, regeneration of.*
- prevention of, 495, 500-501
- transmission of, 261-263
 - in blood transfusion, decision making model for, 883-893
- treatment of, 444, 446, 475-485

- drugs for, 483-484
- vaccines for, 500-501
- virus of. *See Hepatitis C virus.*
- Hepatitis C virus, alcohol interactions
 - with. *See Alcohol, hepatitis C virus interactions with.*
- antigens of, in interferon therapy, 476
- burden of, 260-261
- detection of, 259-260
- genes of, 258-259
- genotypes of. *See Hepatitis C virus, variants of.*
- nomenclature of, 258-259
- quasispecies behavior of, 439-446
- structure of, 258-259
- variants of, 429-449
 - clinical significance of, 434-436
 - genesis of, 437-439
 - hepatocellular injury and, 308
 - identification methodology for, 432-434
 - maintenance of, 437-439
 - multiple infections with, 436
 - nomenclature of, 432-434
 - quasispecies behavior of, 439-446
 - RNA polymerase fidelity and, 440-441
- Hepatitis D, alcohol and, 258, 460
 - chronic, 257-258
 - clinical features of, 456
 - diseases associated with, 258
 - epidemiology of, 257
 - genes of, 459
 - hepatitis B coinfection with, 258, 451-452, 455-456, 459-460
 - interferons in, 472
 - hepatitis C coinfection with, 460
 - HIV infection with, 460
 - incidence of, 257
 - mechanisms of, 455-457
 - natural history of, 455-456
 - pathogenesis of, 456-460
 - patterns of, 457
 - prevalence of, 257
 - prognosis for, 457-460
 - serologic response in, 256-257
 - transmission of, 257
 - virus of. *See Hepatitis D virus.*
- Hepatitis D virus, 451-464
 - antibodies to, 256-257
 - antigens of, 256-257
 - classification of, 451-452
 - genes of, 256, 453-455
 - nomenclature of, 256
 - replication of, 452-453
 - structure of, 256, 451-452
- Hepatitis delta. *See Hepatitis D.*
- Hepatocellular carcinoma, 395-406
 - chemical carcinogens in, 377-394
 - alcohol, 378, 386-390
 - genotoxic, 378-382

- nodule pathology and, 384-386
- nongenotoxic, 383
- geographic distribution of, 396
- in hepatitis B, 255, 395-400
 - alcohol interaction in, 278-280, 292, 377, 388-390, 402
 - carcinogenic mechanisms in, 494-495
 - hepatitis C coinfection with, 401-402
 - liver regeneration and, 327-328
 - pathogenesis of, 493-494
 - prevention of, 495-500
- in hepatitis C, 263-264, 400-403
 - alcohol interaction in, 280-281, 292, 377, 388-390, 402-403
 - carcinogenic mechanisms in, 494-495
 - hepatitis B coinfection with, 401-402
 - liver regeneration and, 327-328
 - pathogenesis of, 493-494
 - prevention of, 495, 500-501
- prevention of, hepatitis vaccines for, 493-505
- resistance phenotype in, 380-382
- Hepatocyte(s), carcinoma of. See *Hepatocellular carcinoma*.
- injury of, in hepatitis B, 307-324
 - animal models for, 309-310
 - hepatitis C coinfection with, 318-319
 - human leukocyte antigen expression and, 310-314
 - interferon in, 311-314
 - patterns of, 307-308
 - viral antigens and, 314-317
- in hepatitis C, 307-324
 - hepatitis B coinfection with, 318-319
 - mediators in, 317-318
 - patterns of, 307-308
- regeneration of. See *Liver, regeneration of*.
- Hepatocyte growth factor, in liver regeneration, 328-330
- Hereditary breast cancer. See *Breast cancer, hereditary*.
- Heta starch, as replacement fluid, in apheresis, 916
 - in granulocyte mobilization, for apheresis, 915-916
- Heteroduplex analysis, in breast cancer, 157
- High molecular weight kininogen, in coagulation, 844-845
- High-pressure liquid chromatography, in mycobacterial identification, 606-607
- HIV infection. See *Human immunodeficiency virus infection*.
- Hodgkin's disease, bcl-2 gene rearrangements in, 41
 - in HIV infection, 4
- Horizontal laminar flow benches, in mycobacteriology, 535-536
- HPA antigens, platelet, 818-819
- Human immunodeficiency virus infection,
 - angiocentric immunoproliferative lesion in, 2
 - diagnosis of, nucleic acid sequence-based amplification in, 94-101
 - in qualitative detection, 94-95
 - in quantitative detection, 95-98
 - performance of, 98-100
 - single-tube, 95-98
 - esophageal candidiasis in, 75
 - hepatitis C coinfection with, 261-262
 - hepatitis D coinfection with, 460
 - Hodgkin's disease in, 4
 - mycobacterial infections in, epidemiology of, 514-516
 - Mycobacterium avium* complex infections in, drug susceptibility testing of, 648-650
 - testing for, informed consent for, 941-942
 - transmission of, in blood transfusion, decision making model for, 883-893
 - prevention of, 787, 977-982
 - screening for, 948-949
 - tuberculosis in, in developing countries, 698-700
- Human leukocyte antigens, hepatocellular injury from, in hepatitis, 310-314
- platelet, 818
- typing of, in platelet transfusions, 805-806, 809
- Human papillomavirus, detection of, multiplex polymerase chain reaction in, 64, 68-69
- Human T-cell lymphotropic virus-1,
 - transmission of, in blood transfusion, prevention of, 787
- Hydroxyethyl starch, as replacement fluid, in apheresis, 916
 - in granulocyte mobilization, for apheresis, 915-916
- 21-Hydroxylase deficiency, 125-137
 - clinical features of, 125-126
 - diagnosis of, 126, 131-132
 - gene involved in, 126-128
 - genotype-phenotype relationships in, 132-135
 - molecular genetics of, 128-131
 - treatment of, 126
- Hypercholesterolemia, apolipoprotein E polymorphism in, 109-110
 - familial, affinity adsorption apheresis in, 921
- Hyperkalemia, in massive transfusions, 878-879
- Hyperlipoproteinemia, apolipoprotein E polymorphism in, 106, 108-110
- Hypocalcemia, in massive transfusions, from citrate effect, 878
- Hypokalemia, in massive transfusions, 878-879

- Hypothermia, in massive transfusions, coagulopathy in, 877-878
- Immune response, in hepatocellular injury, in hepatitis, 307-308, 311-318
- Immunization, intracellular, in gene therapy, 202-205
- Immunoabsorption, in apheresis, 919-921
- Immunodeficiency, from transfusions, massive, 879
prevention of, 789-790
fungal infections in. *See Fungal infections.*
mild, in alcohol consumption, 275
severe combined, gene therapy for, 200-201
- Immunofluorescence assay, platelet, 820-821
- Immunoglobulin(s), intravenous, versus plasma exchange, efficacy of, 919
platelet-associated, direct detection of, 823-824
- Immunoglobulin G, heavy chain of, in bcl-2 gene rearrangement, 27-28
- Immunohistochemical methods, in bcl-2 gene rearrangement detection, 38
- Immunotherapy, for hepatitis B, 475
for neoplasia, in vitro, 205-206
in vivo, 206
- In situ hybridization, in bcl-2 gene rearrangement detection, 38-39
- Indirect tests, of drug susceptibility, of mycobacteria, 643-647
- Indomethacin, in hepatitis C, 484
- Infections, gene therapy for, 202-205
postoperative, from transfusion immunosuppression, 790
- Infectious substances, definition of, 543-544
- Infectious waste management, in mycobacteriology, 541-542
- Inflammatory pseudotumors, of orbit, versus lymphoma, 9
- Informatics, in blood banking, 947-960
in transfusion therapy, 947-960
for blood ordering, 954-956
for compatibility testing, 956-958
for donor screening, 948-951
for inventory management, 952-954
for usage review, 954-956
for validation, 958
- Information systems, for pathology practice networking, 235
- Informed consent, 931-946
for autopsy, 938-939
for legal purposes, 942
for research studies, 942-944
for transfusion therapy, competency in, 936-937
concept of, 932
donor, 939-940
exceptions for, 937-938
for HIV testing, 941-942
general forms for, 933
indications for, 933-934
information needed in, 934-935
liability in, 933
process of, 935-936
recipient, 940-941
signators for, 936-937
standards of, 933-936
state laws on, 935
versus informed refusal, 936
versus nonconsent, 932-933
- Informed refusal, 936
- Injury, hepatocellular. *See Hepatocyte(s), injury of.*
- Inoculation, in mycobacteriology, safety in, 530-531
- Interferons, 465-491
administration of, 466-467
in hepatic fibrogenesis inhibition, 368
in hepatitis B, 467-473
clinical studies of, 468-471
core gene mutants and, 419
endogenous, 311-314
in Asians, 471-472
in liver transplantation, 473
nonresponders to, 472
with cirrhosis, 471
with hepatitis D, 472
in hepatitis C, 435
clinical studies of, 476-481
in liver transplantation, 483
with extrahepatic manifestations, 481-482
in liver regeneration, 332-333
nonresponders to, 472
side effects of, 467
types of, 466
- Interleukins, in alcohol consumption, liver regeneration and, 295-296
in liver regeneration, 352
- International sensitivity index, for prothrombin time, 849
- Interview, of blood donors, computerized, 949-950
- Iron reduction therapy, in hepatitis C, 484
- Iron uptake test, in mycobacterial identification, 583, 590-591
- Irradiation, of blood components, for transfusion complication prevention, 790-792
- Isoelectrofocusing, in apolipoprotein E polymorphism phenotype analysis, 113-114
- Isoniazid, in mycobacterial infections, 641
pharmacokinetics of, 720-721

- Jehovah's Witnesses, refusal of transfusions, 936
- J_H gene, fusion with bcl-2 gene, 28-29
- Kanamycin, pharmacokinetics of, 720-721
- Ketoprofen, in hepatitis C, 484
- Kidney transplantation, affinity adsorption apheresis in, 920-921
- Kinyoun stain, for acid-fast bacteria, 554-555
- Kleihauer-Betke acid elution test, 905
- Ko antigens, platelet, 819
- Labeling, of mycobacterial samples and cultures, 546-548
- Laboratory management, networking in, 227-241
- legal aspects of, 239-240
 - model for, 233-239
 - practice size and, 230-233
 - sociopolitical background for, 227-230
- of hospital-based practices, current health care trends and, 225-226
- test utilization control in, 749-771
- administrative interventions for, 765-768
 - approaches to, 749-750
 - caveats for, 751-752
 - clinical feedback in, 760-762
 - demand reduction in, 759-768
 - educational interventions for, 759-760
 - financial feedback in, 762-763
 - incentives for, 764-765
 - industry performance in, 752-754
 - organizational factors in, 755-756
 - physician profiling in, 763-764
 - published trials of, 758-759
 - quality of care and, 757-758
 - savings estimation in, 754-755
 - test ordering psychology in, 756-757
 - utilization measurement in, 750-751
- Laminin, in liver, 362-363
- Lamivudine, in hepatitis B, 474-475
- Large granular lymphocytosis, DNA analysis of, 16-19
- Lavage, in specimen collection, for mycobacteriology, 552-553
- Legal issues, in blood banking. See *Informed consent.*
- in DNA technology, in forensic testing, 192-193
 - in networking in laboratory management, 239-240
- Leprosy, epidemiology of, 513
- Leukemia, bcl-2 gene rearrangements in, 24
- platelet transfusions in, 798
 - recurrent, allogeneic stem cell transplantation in, 913
- Leukocytes, polymorphonuclear, in hepatic extracellular matrix degradation, 365
- removal of, from blood components, 783-784
 - for pathogen removal, 787-789
 - for platelet refractoriness, 785-786
 - platelets, 801-803
- Liability, hospital versus physician, 933
- Li-Fraumeni syndrome, breast cancer in, 147
- Ligase chain reaction, 90
- in sexually transmitted disease diagnosis, 62-63
- Linkage analysis, in breast cancer detection, 152-153
- Lipid disorders, apolipoprotein E polymorphism and. See *Apolipoprotein E, polymorphism of.*
- Lipoprotein receptor binding, apolipoprotein E polymorphism and, 106-107
- Liver, alcohol metabolism in, 275
- alcoholic disease of, hepatitis virus interactions in. See *Alcohol, hepatitis B (or C) interactions with.*
 - candidiasis of, in immunodeficiency, 75
 - fibrogenesis of. See *Fibrogenesis, hepatic.*
 - necrosis of, regeneration in, 326-327
 - nodules in, carcinoma development from, 379-380, 384-386
 - regeneration of, 325-339, 341-360
 - alcohol effects on, 293
 - cytokines and, 295-297
 - receptor-mediated responses in, 297-299 - cytokines in, 295-297, 328-333, 351-354
 - epithelial cells in, 326-328
 - extracellular matrix in, 333-334
 - functional maintenance during, 345-347
 - hepatocyte growth factor in, 328-330
 - in cirrhosis, 355
 - in hepatitis, 354
 - in transplantation, 354-355
 - interferons in, 332-333
 - primary growth-response gene induction in, 342-344
 - transcription factor activation in, 347-351
 - transforming growth factors in, 330-332
 - tumor necrosis factor in, 331
- transplantation of, hepatitis B in, interferon in, 473
- hepatitis C in, treatment of, 483
 - regeneration in, 354-355

- Lowenstein-Jensen culture media, for mycobacteria, 559-560
- Luciferase test, of drug susceptibility, of mycobacteria, 646-647
- Lupus anticoagulants, measurement of, 858-859
- Lymphocytes, modified with tumor necrosis factor, in gene therapy, for neoplasia, 206
- Lymphocytosis, large granular, DNA analysis of, 16-19
- Lymphoid hyperplasia, versus lymphoma, 9-10
- Lymphoid malignancies. See also *Lymphoma*.
bcl-2 gene rearrangements in. See *bcl-2 gene, rearrangements of*.
- Lymphoma, bcl-2 gene rearrangements in, 23-24
diffuse, 40
follicular, 39-40
prognostic value of, 42-43
small noncleaved cell, 40-41
cutaneous T-cell, photopheresis in, 921-922
DNA analysis in, of mucosa-associated lymphoid tissue, 5-7
of skin, 11-13
small cell cleaved, 7-11
- Lymphoproliferative disorders, B-cell, in transplantation, 13-16
- Lysosomal storage diseases, gene therapy for, 200-201
- MacConkey agar, in mycobacterial identification, 583, 591
- Malaria, transmission of, in blood transfusion, prevention of, 977
- Malnutrition, in alcohol abuse, hepatocellular sensitivity to, 292
- Managed care, pathology services in, networking in. See *Laboratory management, networking in*.
- Marketing, for pathology practice networking, 238
- Mathematical calculations, for blood banking. See *Transfusion therapy, mathematical calculations in*.
- MB/BacT System, for mycobacterial culture, 562-563
- Metalloproteinases, in hepatic extracellular matrix degradation, 365
- Microaggregate filtration, of blood component cells, for transfusion, 783-784
- Microbial Identification System, in mycobacteriology, 605-606
- Microcolony method, for mycobacterial culture, 563-564, 604
- Microscopy, in mycobacteriology, 553-554
in developing countries, 706-707
- Middlebrook agar, for mycobacterial culture, 559-560
- Minimum inhibitory concentration, determination of, for mycobacteria, 642, 645-646
for *Mycobacterium avium* complex, 651-652
- Mitochondrial DNA sequencing, in forensic testing, 190-191
- Mixed passive hemagglutination assay, for platelet antibodies, 821
- Molecular pathology. See *DNA technology*.
- Monoclonal antibody-specific immobilization of platelet antigens assay, 823
- Mucopolysaccharidosis, gene therapy for, 200-201
- Mucormycosis, in immunodeficiency, 78-79
clinical features of, 78-79
- Mucosa-associated lymphoid tissue, lymphoma of, DNA analysis in, 5-7
- Muir-Torre syndrome, breast cancer in, 147
- Multidrug-resistant gene, modification of, in chemoprotection, 207
- Muscular dystrophy, gene therapy for, 200-201
- Mycobacterial growth indicator tubes, 560-561
- Mycobacterial infections. See also *Tuberculosis*.
atypical. See also specific organism.
epidemiology of, 699
epidemiology of, 513-516
- Mycobacteriology, amplification techniques in, 617-639
Association of State and Territorial Public Health Laboratory Directors recommendations on, 731-743
automation in, culture equipment, 560, 562-563
cultures in. See under *Cultures*.
drug monitoring in, 717-729
drug susceptibility testing in. See *Drug susceptibility testing, of mycobacteria*.
epidemiology and, 513-516
future developments in, 522-523
identification techniques in, conventional, 569-601
approach to, 570
arylsulfatase method, 572, 578, 581, 583, 587
carbon usage measurement, 583, 587-588
catalase methods, 572, 578, 581, 583, 588-589
colonial morphology, 572, 578, 581, 583, 589-590

- growth rate categorization, 570-571, 581
- growth rate determination, 590
- iron uptake measurement, 583, 590-591
- MacConkey agar growth rate, 583, 591
- NAP test, 591-592
- niacin production measurement, 572, 578, 581, 592
- nitrate reduction rate, 572, 578, 581, 583, 592-593
- nonphotochromogenicity in, 571-578
- photochromogenicity in, 570-571, 578-580
- pigment production, 572, 578, 581, 583, 594-594
- polymyxin B inhibition test, 583, 594
- pyrazinamide hydrolysis, 572, 578, 581, 594-595
- rapid growing capability, 582-586
- role of, 569-570
- scotochromogenicity in, 580-582
- sodium chloride tolerance, 581, 583, 595
- species isolated in, 571
- TCH resistance, 573, 578, 581, 596-597
- tellurite reduction, 573, 595-596
- temperature studies, 572-573, 578, 581, 583, 596
- Tween 80 hydrolysis, 573, 578, 581, 597
- urease test, 573, 578, 581, 597-598
- in developing countries, 707-708, 711-712
- rapid, 603-615
- gas-liquid chromatography in, 605-606
- high-pressure liquid chromatography in, 606-607
- microcolony method in, 563-564, 604
- p-nitro- α -acetylaminob- β -hydroxypropiphenone test in, 604-605
- nucleic acid probes in, 607-608
- nucleic acid sequencing in, 608-611
- quality control of, 662
- in developing countries, 520-522, 697-716
- disease control and, 700-701
- drug susceptibility testing, 707
- epidemiologic considerations in, 698-699
- identification testing, 707-708
- intermediate level laboratory in, 704
- laboratory networks in, 702-705
- new methods for, 710-712
- peripheral level laboratory in, 704
- protocols for, 712-713
- quality assurance in, 708-710
- reference laboratory in, 703-704
- services available for, 701-702
- specimen collection units in, 704-705
- technical standards and procedures for, 705-707
- laboratory for, 513-525
- polymerase chain reaction in, 617-639
- protocols for, in developing countries, 712-713
- in industrialized countries, 677-695
- algorithm for, 679-686
- clinical predictors versus test pathways, 692-693
- cost-effective strategies, 686-689
- extent of service, 678-679
- future trends in, 689-690
- reference laboratory usage and, 686
- quality assurance in, 657-675
- safety in, 527-550
- services available for. See also *Mycobacteriology*, in developing countries.
- in United States, 516-520
- specimen processing for, 551-567
- Mycobacterium abscessus*, identification of, 583
- Mycobacterium africanum*, identification of, 572-573
- Mycobacterium asiaticum*, identification of, 578-579
- Mycobacterium avium* complex, drug susceptibility testing of, 648-652
- epidemiology of, 515-516
- identification of, 572-574, 581
- Mycobacterium avium-intracellulare-scrofulaceum*, identification of, 580
- Mycobacterium bovis*, identification of, 572-573
- Mycobacterium branderi*, identification of, 572-575
- Mycobacterium celatum*, identification of, 572-573, 575
- Mycobacterium chelonae*, identification of, 583-585
- Mycobacterium conspicuum*, identification of, 572-573, 575
- Mycobacterium flavescens*, identification of, 580-581, 583
- Mycobacterium fortuitum* complex, identification of, 583-585
- Mycobacterium fortuitum-chelonae*, drug susceptibility testing of, 652-653
- Mycobacterium gastri*, identification of, 572-573, 575
- Mycobacterium genavense*, identification of, 572-573, 575
- Mycobacterium gordonae*, identification of, 580-582

- Mycobacterium gordonae* (Continued)
isolation of, 559
- Mycobacterium haemophilum*, identification of, 572-573, 576
- Mycobacterium interjectum*, identification of, 581-582
- Mycobacterium intermedium*, identification of, 578-579
- Mycobacterium kansasii*, identification of, 578-579
- Mycobacterium lentiflavum*, identification of, 582
- Mycobacterium malmoense*, identification of, 572-573, 576
- Mycobacterium marinum*, drug susceptibility testing of, 652-653
identification of, 578-579
- Mycobacterium mucogenicum*, identification of, 583
- Mycobacterium neoaurum*, identification of, 583, 585
- Mycobacterium paratuberculosis*, identification of, 576
- Mycobacterium phlei*, identification of, 585
- Mycobacterium scrofulaceum*, identification of, 581-582
- Mycobacterium shimoidei*, identification of, 572-573, 576-577
- Mycobacterium simiae*, identification of, 572-573, 578-580
- Mycobacterium smegmatis*, identification of, 583, 585
- Mycobacterium szulgai*, identification of, 578, 581-582
- Mycobacterium terrae* complex, identification of, 572-573, 577
- Mycobacterium thermoresistibile*, identification of, 583, 585
- Mycobacterium triviale*, identification of, 572-573, 577
- Mycobacterium tuberculosis* complex. See also *Tuberculosis*.
bacteriology of. See *Mycobacteriology*.
detection of, polymerase chain reaction in. See *Polymerase chain reaction*, in *mycobacteriology*.
drug susceptibility testing of, 643-648
identification of, 571-574
infectious dose of, 529
- Mycobacterium ulcerans*, identification of, 572-573, 577
- Mycobacterium xenopi*, identification of, 572-573, 577-578, 581
- Mycolic acids, chromatography of, 607-608
- Mycosis fungoides, DNA analysis of, 11-13
- Myelosuppressive drugs, in stem cell mobilization, for apheresis, 909-910
- Necrosis, liver, regeneration in, 326-327
- Negligence, versus battery, 932-933
- Neisseria gonorrhoeae*, detection of, multiplex polymerase chain reaction in, 64-68
- Neocytes, in transfusion, estimation of, 897
- Neonatal alloimmune thrombocytopenic purpura, platelet antibody detection in, 825-827
- Neonates, hepatitis B transmission to, 253
- Neoplasia, gene therapy for, 205-208
- Nephelometry, in platelet antibody detection, 825
- Networking, in pathology services. See *Laboratory management, networking in*.
- New Oxford assay, for coagulation factor inhibitors, 857
- Niacin production test, in mycobacterial identification, 572, 578, 581, 592
- Nitrate reduction test, in mycobacterial identification, 572, 578, 581, 583, 592-593
- p-Nitro- α -acetylamino- β -hydroxypropionophenone test, in mycobacterial identification, 591-592, 604-605
- Nodules, hepatic, carcinoma development from, 379-380, 384-386
- Nomenclature, standardized, for pathology practice networking, 237
- Nongenotoxic carcinogens, in hepatocellular carcinoma, 383
- Nonphotochromogens, identification of, 571-578
- Nosocomial infections, candidiasis, epidemiology of, 82-85
- Nuclear factor kappa B, activation of, in liver regeneration, 349-351
- Nucleic acid probes, in mycobacterial identification, 607-608
- Nucleic acid sequence-based amplification, 89-103
amplification in, 92, 94
in HIV infection, 94-101
in qualitative detection, 94-95
in quantitative detection, 95-98
performance of, 98-100
single-tube, 95-98
in sexually transmitted disease diagnosis, 62-63
methods for, 90-91
nucleic acid isolation in, 91-92
product detection in, 94
- Nucleic acid sequencing, in mycobacterial identification, 608-611
- Nutrition, in alcohol abuse, hepatocellular sensitivity to, 292
- Oligonucleotides, antisense, in gene therapy, 203

- Oral cavity, candidiasis of, in immunodeficiency, 75
- Oral contraceptives, thrombosis risk in, factor V gene mutation and, 176
- Orbit, lymphoma of, 7-11
- Osteopetrosis, in carbonic anhydrase II deficiency, genetic studies of, 213-214
- Oval cells, in liver regeneration, 326-327
- Ovarian cancer, hereditary breast cancer and, 140, 143, 145-147
- Oxygen-hemoglobin dissociation curve, shifting of, in massive transfusions, 875-876
- P1A antigens, platelet, 818-819
- Packaging, of mycobacterial materials, 544-546
- Papillomavirus, detection of, multiplex polymerase chain reaction in, 64, 68-69
- Paternity testing, consent for, 942
- PCR. See *Polymerase chain reaction*.
- Pencyclovir, in hepatitis B, 474
- Pentastarch, as replacement fluid, in apheresis, 916
- in granulocyte mobilization, for apheresis, 915-916
- Pen/Yuk antigens, platelet, 819
- Peripheral blood stem cells. See *Stem cells*.
- Peripheral vascular disease, apolipoprotein E polymorphism in, 112
- Peritonitis, candidal, in immunodeficiency, 76
- Perlecan, in liver, 363
- Peroxisome proliferators, in hepatocellular carcinoma, 383
- Personal protective equipment, for mycobacteriology, 540-541
- Personnel, laboratory, in state laboratories, for mycobacteriology, 733-734
- tuberculin tests for, 542
- tuberculosis incidence in, 528
- Phagocytosis, in hepatic extracellular matrix degradation, 365
- Pharmacodynamics, of antimycobacterial drugs, 721
- Pharmacokinetics, of antimycobacterial drugs, 718-721
- Phlebotomy, in hepatitis C, 484
- Photochromogenicity, of mycobacteria, identification techniques based on, 570-571, 578-580
- Photopheresis, 921-922
- Physicians, laboratory test use by, control of. See *Laboratory management, test utilization control in*.
- Pigment production, in mycobacterial identification, 572, 578, 581, 583, 593-594
- Plasma agarose method, for coagulation factor inhibitor assay, 857-858
- Plasma mixing studies, in coagulation disorders, 852-853
- Plasma reduction, in blood component modification, for transfusion, 782
- Plasma volume, calculation of, 897
- Plasmapheresis, angiotensin-converting enzyme inhibitors effects in, 917-918
- plasma removal in, calculations for, 905
- Plasmin, in hepatic extracellular matrix degradation, 365
- Platelet(s), antibodies to, 817-835
- antigens corresponding to, 817-820
- detection of, in autoimmune thrombocytopenic purpura, 829-831
- in drug-dependent thrombocytopenia, 831-832
- in neonatal alloimmune thrombocytopenic purpura, 825-827
- in post-transfusion purpura, 827-828
- in pseudothrombocytopenia, 832-833
- in refractoriness, 828-829
- methods for, 820-825
- to nonspecific antigens, 817-818
- to platelet-specific antigens, 818-820
- antigens of, assay of, 823
- cryptic, 820
- nonspecific, 817-818
- platelet-specific, 818-820
- typing of, 825
- in coagulation, 839-840
- synthetic analogs of, 811
- transfusion of, 797-816
- ABO matching for, 806-807
- administration of, 808
- alternatives to, 811
- autologous, 809-810
- components for, 799-804
- filtered cells in, 783-784
- in refractory patient, 808-810
- increments for, 902-903
- indications for, 797-799
- initiation of, 804-806
- irradiated cells in, 790-792
- leukocyte-reduced, 801-803
- ordering of, 955-956
- platelet crossmatching in, 809-810
- prophylactic, 798-799
- protocol for, 804-810
- refractoriness in, 828-829
- prevention of, 785-786
- Rh type matching for, 807
- single-donor versus multiple-donor, 800-801
- storage additives for, 803-804

Platelet(s) (Continued)

- storage time and, 808
- transfusion reactions in, prevention of, 786
- washed cells in, 781-782
- Platelet immunofluorescence assay, 820-821
- Platelet-associated immunoglobulins, direct detection of, 823-824
- Platelet-derived growth factor, in stellate cell proliferation, 368-369
- Plateletpheresis, 800-801
- Polymerase, in hepatitis B, hepatocellular injury from, 317
- Polymerase chain reaction, 90
 - automation of, 217-219
 - costs of, 52
 - enthusiasm for, 50-51
 - in apolipoprotein E polymorphism genotype analysis, 114, 116
 - in bcl-2 gene rearrangement detection, 35-39
 - in breast cancer gene detection, 149-150
 - in candidiasis diagnosis, 77-78
 - in *Chlamydia trachomatis* detection, evaluation of, 52-59
 - in factor V gene mutation detection, 178-180
 - in forensic testing, 188-189
 - in hepatitis C virus detection, 259-260
 - in hepatitis C virus genotyping, 433-434
 - in 21-hydroxylase deficiency diagnosis, 128-129, 131-132
 - in mycobacteriology, 617-639
 - amplification approaches in, 621-623
 - amplification targets in, 623-624
 - cell lysis in, 619
 - commercial systems for, 630-631
 - definition of, 618-619
 - detection schemes in, 625-626
 - developmental challenges in, 629
 - extraction methods in, 619-620
 - implementation of, 634-637
 - in developing countries, 711
 - in-house versus commercial, 631
 - nested, 621-623
 - principles of, 617-619
 - purification methods in, 619-620
 - sensitivity and specificity of, 626-629
 - versus Gen-Probe MTD system, 632-634
 - miniaturization of, 217
 - multiplex, in sexually transmitted disease diagnosis, 61-71
 - Chlamydia trachomatis*, 64-68
 - commercial tests for, 62-63
 - human papillomavirus, 64, 68-69
 - Neisseria gonorrhoeae*, 64-68
 - principles of, 63
 - Ureaplasma urealyticum*, 69
 - sequence-specific, in factor V gene mutation detection, 180-183
 - skepticism about, 51-52
- Polymyxin B, in mycobacterial identification, 583, 594
- Potassium, imbalance of, in massive transfusions, 878-879
- Pregenome, of hepatitis B virus gene, 409
- Prekallikrein, in coagulation, 844-845
- PRELOG expert system, for blood donor suitability, 951
- Primer-mediated restriction endonuclease site generation, in factor V gene mutation detection, 180
- Probes, DNA, in mycobacteriology, quality control of, 661
 - nucleic acid, in mycobacterial identification, 607-608
- Proficiency testing, in mycobacteriology, 669-672
- Proportion method, for drug susceptibility testing, of mycobacteria, 644-645
- Prostaglandin(s), in hepatic fibrogenesis inhibition, 368
 - in stellate cell proliferation, 369-370
- Prostaglandin E, in hepatitis B, 474
- in hepatitis C, 483-484
- Protein A, activated, resistance to. See *Activated protein C and/or A*.
- Protein C, activated, resistance to. See *Activated protein C and/or A*.
- evaluation of, 861-862
- deficiency of, evaluation of, 859-860
- in coagulation regulation, 846-847
- Protein S, deficiency of, evaluation of, 860-861
 - in coagulation regulation, 847
 - in hemostasis, 171
- Protein truncation testing, in breast cancer, 159
- Proteinases, in hepatic extracellular matrix degradation, 365
- Proteoglycans, in liver, 363-364
- Prothrombin time, 848-849
 - abnormal, differential diagnosis of, 850-852
- Prothrombinase complex, in coagulation, 840
- Protocols, for mycobacteriology. See under *Mycobacteriology*.
- Pseudothrombocytopenia, platelet antibodies in, 832-833
- Pseudotumors, inflammatory, of orbit, versus lymphoma, 9
- Purification, in polymerase chain reaction, 619-620
- Purpura, autoimmune thrombocytopenic, platelet antibodies in, 829-831
- neonatal alloimmune thrombocytopenic, platelet antibody detection in, 825-827

- post-transfusion, 827-828
 intravenous immunoglobulin in, 919
 Pyrazinamide, in mycobacterial
 identification, 572, 578, 581, 594-595
 in mycobacterial infections, 641-642
 in susceptibility testing, 646
 pharmacokinetics of, 720-721
- Q-beta replicase assay, 90
 in sexually transmitted disease diagnosis, 62-63
- Quality assurance, in blood banking. See
*Transfusion therapy, error detection and
 reduction in.*
- in forensic testing, 191-192
 in mycobacteriology, 657-675
 Association of State and Territorial
 Public Health Laboratory Direc-
 tors recommendations on, 739-
 742
 definition of, 657
 in developing countries, 708-710
 in therapeutic drug monitoring, 725
 proficiency testing in, 669-672
 quality control in, 658-663
 quality improvement in, 664
 specimen-related issues in, 664-667
 test sensitivity and, 667-668
 test usage optimization in, 669
 test utilization reduction and, 757-758
 turnaround times and, 668-669
 standardized, for pathology practice net-
 working, 226-237
- Quality control, in mycobacteriology,
 658-663
- Quality improvement, in
 mycobacteriology, 664
- Quasispecies swarm, of hepatitis C virus,
 439-446
- Radiometric method, in drug susceptibility
 testing, in developing countries,
 711-712
 of atypical mycobacteria, 653
 of *Mycobacterium avium* complex,
 649-651
- Rapid techniques, in mycobacteria
 identification. See *Mycobacteriology,
 identification techniques in, rapid.*
- Rapidly growing mycobacteria,
 identification of, 582-586
- Red blood cells, alloantibodies to,
 detection of, 901-902
 for transfusion, filtered, 783-784
 frozen-thawed-deglycerolized, 782-783
 irradiated, 790-792
 washed, 781-782
 kinetics of, calculations for, 897
 mass of, calculation of, 896
- Red cell adherence test, solid-phase, for
 platelet antibodies, 822-823
- Reference laboratories, for
 mycobacteriology, 686
 in developing countries, 703-704
- Refusal, informed, 936
- Regeneration, of liver cells. See *Liver,
 regeneration of.*
- Regulations, for DNA technology, in
 forensic testing, 191-192
 for mycobacterial sample handling, 544
- Rejection, in transplantation, photopheresis
 in, 922
- Renal tubular acidosis, in carbonic
 anhydrase II deficiency, genetic
 studies of, 213-214
- Reporting, of errors, in blood banking,
 965-967
 standardized procedures for, in pathol-
 ogy practice networking, 237
- Reptilase time test, in coagulation
 disorders, 854
- Research, informed consent in, 942-944
- Respirators, for mycobacteriology, 541
- Restriction endonuclease fingerprinting, in
 breast cancer, 157
- Restriction endonuclease site generation,
 primer-mediated, in factor V gene
 mutation detection, 180
- Restriction enzyme analysis, in fungal
 typing, 81-82
- Restriction fragment length polymorphism,
 in apolipoprotein E polymorphism
 genotype analysis, 116
 in factor V gene mutation detection,
 178-180
 in forensic testing, 188
 in fungal typing, 82
- Rh type matching, in platelet transfusions,
 807
- Ribavirin, in hepatitis C, 484
- Ribozymes, in gene therapy, 203
- Rifabutin, pharmacokinetics of, 720-721
- Rifampin, pharmacokinetics of, 720-721
- RNA, amplification of, polymerase chain
 reaction in. See *Polymerase chain
 reaction.*
 as decoy, in gene therapy, 204
- RNA polymerase, in hepatitis C virus
 replication, 440-444
- Rocket electrophoresis, for platelet
 antibodies, 824
- Rule of 3, in transfusion therapy, 895
- Rule of 7, in transfusion therapy, 895-896
- Safety, in mycobacteriology, 527-550
 director role in, 542

Safety (Continued)

- in level 2 laboratory, 538-539
- in level 3 laboratory, 539-540
- in routine procedures, 530-531
- in specimen transport, 543-548
- infectious waste management in, 541-542
- information sources for, 548
- medical surveillance in, 542-543
- personal protective equipment in, 540-541
- primary biocontainment in, 531-538
- relative risks versus sample type, 528-530
- secondary biocontainment in, 538
- training for, 543
- in transfusion therapy, 975-988
 - appropriate use in, 984-985
 - component modification in, 985
 - decision making model for, 883-893
 - disease transmission reporting in, 983-984
 - follow-up of donors and inventory in, 982-983
 - selection of donors in, 975-978
 - testing of donor blood in, 978-982
- Saliva, hepatitis C virus in, 262
- Salt wasting, in congenital adrenal hyperplasia, 134
- Schizophrenia, gene therapy for, 202
- Scotocromogens, identification of, 580-582
- Secreted protein acidic and rich in cysteine (SPARC), in liver, 363
- Sepsis, transfusion-transmitted, 788-789
- Septi-Chek MB System, for mycobacterial culture, 564
- Sequence-specific polymerase chain reaction, in factor V gene mutation detection, 180-183
- Severe combined immunodeficiency, gene therapy for, 200-201
- Sexually transmitted diseases, diagnosis of, multiplex polymerase chain reaction in, 61-71
 - Chlamydia trachomatis*, 64-68
 - commercial tests for, 62-63
 - human papillomavirus, 64, 68-69
 - Neisseria gonorrhoeae*, 64-68
 - principles of, 63
 - Ureaplasma urealyticum*, 69
- Sézary syndrome, photopheresis in, 922
- Signal transduction, in liver cell regeneration, alcohol effects on, 293
- Signal transduction and activator of transcription (stat3), activation of, in liver regeneration, 351
- Single-stranded conformation polymorphism analysis, in breast cancer, 155
- Skin, lymphoma of, DNA analysis of, 11-13
- Slide culture test, of drug susceptibility, of mycobacteria, 647-648
- Slot blot test, in breast cancer gene mutation detection, 160
- Sly disease, gene therapy for, 200-201
- Smears, acid-fast. See *Acid-fast bacteria*, smears of.
- Sodium chloride tolerance test, in mycobacterial identification, 581, 583, 595
- Solid-phase red cell adherence test, for platelet antibodies, 822-823
- Southern blot analysis, in bcl-2 gene rearrangement detection, 31-37
- in breast cancer, 158
- SPARC, in liver, 363
- Specimens, for mycobacteriology, 551-567
 - collection of, 551-553
 - in developing countries, 704-705
 - cross-contamination of, 665-667
 - decontamination of, 558-559, 660
 - microscopic examination of, 553-554
 - in developing countries, 706-707
 - processing of, 557-559
 - cost-effectiveness in, 687-688
 - quality assurance in, 664-667
 - safe handling of, 543-548
- Spill clean-up, in mycobacteriology, 541-542
- Sputum, mycobacterial studies of,
 - collection of, 552
 - sample handling in, 529
 - for polymerase chain reaction, 619-620
- Stains, for acid-fast bacteria, 554-555
- Standard operating procedures, deviations from, in blood banking. See *Transfusion therapy*, error detection and reduction in.
- Stat3 (signal transduction and activator of transcription), activation of, in liver regeneration, 351-352
- Stellate cells, function of, 366
- proliferation of, 366-370
- Stem cells, apheresis-derived, 907-914
 - advantages of, 908
 - allogenic transplantation of, 912-914
 - CD34+ cell measurement in, 910-911
 - mobilization of, 908-910
 - yield optimization in, 911-912
- Stool specimens, for mycobacteriology, 553
- Streptomycin, pharmacokinetics of, 720-721
- Stroke, apolipoprotein E polymorphism in, 112
- Stromelysins, in hepatic extracellular matrix degradation, 365

- Susceptibility testing, of mycobacteria. See *Drug susceptibility testing, of mycobacteria*.
- Syndecans, in liver, 363-364
- T lymphocytes, CD34+, measurement of, in stem cell transplantation, 910-911
- gene rearrangement in, in hematopoietic disorders. See *Hematopoietic disorders*.
- in hepatocellular injury, in hepatitis, 314-315, 318
- TCH test, in mycobacterial identification, 573, 578, 581, 596-597
- Telangiectasia-ataxia, breast cancer in, 148
- Teleconferencing, for pathology practice networking, 235-236
- Tellurite reduction, in mycobacterial identification, 573, 595-596
- Temperature studies, in mycobacterial identification, 572, 578, 581, 583, 596
- Tenascins, in liver, 363
- Tenase complex, in coagulation, 840
- Tests, physician use of, control of. See *Laboratory management, test utilization control in*.
- Therapeutic privilege, informed consent and, 937-938
- Thiacetazone, pharmacokinetics of, 720-721
- Thrombin, in coagulation, 839, 843
- Thrombin time, 853-854
- Thrombocytopenia, affinity adsorption apheresis in, 920
- in cytokine mobilization, of stem cells, 912-913
- in massive transfusions, 876-877
- platelet antibodies in, autoimmune, 829-831
- detection of, 825-827
- drug-dependent, 831-832
- platelet transfusions in. See *Platelet(s), transfusions of*.
- post-transfusion, platelet antibodies in, 827-828
- refractory, platelet transfusions in, 808-810
- Thrombophilia, in activated protein C and A resistance, 171-173
- Thrombosis, multifactorial, gene mutations in, 176
- Tissue engineering, gene therapy in, 208
- Tissue factor pathway inhibitor, in coagulation regulation, 845
- TP53 gene, DNA analysis of, direct, 153-156
- functional detection of mutations of, 158-159
- tests for, 149, 151-152
- mutations of, in ataxia-telangiectasia, 148
- in hereditary breast cancer, 142, 147-148
- Training, for error detection and reduction, in blood banking, 964-965
- in mycobacteriology, Association of State and Territorial Public Health Laboratory Directors recommendations for, 739-741
- for safety, 543
- Transcription factors, activation of, in liver regeneration, 347, 349
- Transcription-mediated amplification, in mycobacteriology, 632-634
- Transforming growth factors, in hepatic fibrogenesis, 367
- in liver regeneration, 330-332
- in stellate cell proliferation, 368-369
- Transfusion therapy, apheresis for. See *Apheresis*.
- bacterial contamination in, 984-985
- component modifications in, 781-795
- filtered cells in, 783-784
- for alloimmunization prevention, 785-786
- for immunomodulation prevention, 789-790
- for infection transmission prevention, 786-789
- for refractoriness to platelets, 785-786
- for transfusion reaction prevention, 784-785
- frozen-thawed-deglycerolized cells, 782-783
- irradiated cells in, 790-792
- washed cells in, 781-782
- disease transmission. See also *Human immunodeficiency virus infection*; specific diseases, e.g., *Hepatitis B*.
- component modification in, 786-789
- disease transmission in, bacterial, 788-789
- error detection and reduction in, 961-973
- corrective action in, 967-972
- error definition for, 961
- organization for, 962-964
- personnel training and competency for, 964-965
- preventive measures in, 967-972
- process parameter definition in, 964
- reporting in, 965-967
- exchange, whole blood reconstitution for, 898-899
- granulocyte, 914-916
- informatics in. See *Informatics*.
- informed consent in. See *Informed consent*.

Transfusion therapy (*Continued*)

- massive transfusions in, 873-882
 - acid-base imbalance in, 876
 - citrate effect in, 878
 - clinical problems with, 875-879
 - coagulation abnormalities in, 876-878
 - definition of, 873
 - fluid therapy with, 874
 - hemoglobin dissociation curve shifts in, 875-876
 - hemorrhage physiology and, 873-874
 - immunosuppression in, 879
 - potassium imbalance in, 878-879
 - treatment protocol for, consultation on, 879-881
- mathematical calculations in, 875-906
 - antibody specificity confidence, 901-902
 - blood volume, 896
 - clotting factor activity levels, 903-905
 - compatible crossmatch probability, 901
 - fetal-maternal hemorrhage volume estimation, 905
 - for exchange transfusion, 898-899
 - hemoglobin increment after transfusion, 898
 - plasma removal in plasmapheresis, 905
 - plasma volume, 897
 - platelet transfusion increments, 902-903
 - probability of transfusion event, 899-901
 - red cell kinetics, 897
 - red cell mass, 896
 - rule of 3, 895
 - rule of 7, 895-896
- platelets in. *See Platelet(s).*
- purpura after, intravenous immunoglobulin in, 919
 - platelet antibodies in, 827-828
- reactions in, prevention of, component modification in, 784-785
 - probability of, 899-901
- refusal of, 936
- safety of, 975-988
 - appropriate use in, 984-985
 - component modification in, 786-789, 985
 - decision making model for, 883-893
 - disease transmission reporting in, 983-984
 - follow-up of donors and inventory in, 982-983
 - selection of donors in, 975-978
 - testing of donor blood in, 978-982
 - testing in, decision making for, model for, 883-893
- Transplantation, B-cell lymphoproliferative disorder in, 13-16

- extracellular, gene therapy in, 208
- fungal infections in, 79
- kidney, affinity adsorption apheresis in, 920-921
- liver, hepatitis B in, interferon in, 473
 - hepatitis C in, treatment of, 483
- regeneration in, 354-355
- rejection in, photopheresis in, 922
- stem cell, allogeneic, 912-914
- Transport, of mycobacterial samples and cultures, 543-548
- Triglycerides, blood levels of, in
 - apolipoprotein E polymorphism, 107
- Tuberculin tests, for laboratory personnel, 542
- Tuberculosis, bacteriology of. *See Mycobacteriology.*
 - clinical features of, test pathways and, 691
 - control of, in developing countries, 700-701
 - drug-resistant, 515
 - in developing countries, 699-701
 - epidemiology of, 513-516, 698-699
 - in laboratory personnel, 528
 - HIV infections with, 514-516
- Tumor necrosis, in lymphocyte
 - modification, in gene therapy, for neoplasia, 206
- Tumor necrosis factors, in alcohol
 - consumption, 275-276, 295-297
 - liver regeneration and, 295-297, 299-301
 - in hepatitis B, 311, 314
 - in liver regeneration, 331
- Tumor suppressor genes, in gene therapy, for neoplasia, 207
 - inactivation of, in breast cancer, 140
- Turbidimetric broth-dilution method, for drug susceptibility testing, of
 - Mycobacterium avium* complex, 651-652
- Tween 80 hydrolysis test, in mycobacterial identification, 573, 578, 581, 597
- Ultraviolet radiation, of blood
 - components, 791-792
 - with apheresis, in cutaneous T-cell lymphoma, 921-922
- Undulin, in liver, 363
- Ureaplasma urealyticum*, detection of,
 - multiplex polymerase chain reaction in, 69
- Urease test, in mycobacterial identification, 573, 578, 581, 597-598
- Urine specimens, for mycobacteriology, 553
 - decontamination of, 559
- Ursodeoxycholic acid, in hepatitis C, 484

- Utilization review, standardized, for
pathology practice networking, 236
- Vaccination, for hepatitis B, 495-500
for hepatitis C, 500-501
intracellular, in gene therapy, 202-205
- Vascular disease, apolipoprotein E
polymorphism in, 112
- Virilization, in congenital adrenal
hyperplasia, 126, 134
- Vitamin K-dependent coagulation factors,
838-839
- Volume replacement, with massive
transfusions, 874
- Washing, of blood component cells,
781-782
- Waste, infectious, management of, in
mycobacteriology, 541-542
- Whole blood, reconstitution of, for
exchange transfusion, 898-899
- Woodchuck hepatitis virus, 310
- Wound infections, candidal, in
immunodeficiency, 77
- X antigen, of hepatitis B virus, alcohol
and, 275, 277, 279-280
as carcinogen, 494
gene of, 409, 411, 421
in hepatocellular injury, 316-317
- Yeast functional assay, in breast cancer,
159
- Zephiran, in mycobacterial specimen
decontamination, 558
- Ziehl-Neelsen stain, for acid-fast bacteria,
554-555
- Zygomycosis, in immunodeficiency, 78-79
clinical features of, 78-79